ONK Therapeutics
Biotechnology ResearchView the employees at
ONK Therapeutics-
Sarah Brophy Senior Scientist at ONK Therapeutics
-
Top 5%
Irene Minas Laboratory Assistant at ONK Therapeutics-
Rising Star
David O'Donnell Biopharmaceutical professional with extensive experience in management, research, PD, CMC and manufacturing roles-
Peabody, Massachusetts, United States
-
Rising Star
David Hardwicke Program Management & CI @ ONK Therapeutics-
Galway, County Galway, Ireland
-
Rising Star
Venkat Kasturi Scientist | CAR-T/NK | Bispecific antibodies | Assay development cell and gene therapy-
County Galway, Ireland
-
Top 10%
Overview
ONK Therapeutics, is an innovative cell therapy company dedicated to developing a next generation of off-the-shelf, dual-targeted NK cell therapy platform targeting hematological malignancies and solid tumors. The Company was founded in 2015, by Prof. O’Dwyer MD, of NUI Galway, an expert in translational multiple myeloma research, the tumour microenvironment, and exploitation of NK cells as cellular immunotherapy. Its core proprietary platform is based on a dual-targeted NK cell expressing both a chimeric antigen receptor (CAR) targeting a known tumour antigen and a TNF related apoptosis inducing ligand variant (TRAILv) targeting the death receptor pathway (i.e. DR4 or DR5). This promising new approach has the potential to enhance efficacy by addressing both intrinsic (e.g. CAR engagement of a tumor specific antigen) and extrinsic (e.g. signalling through the death receptor pathway) apoptotic pathways, and to reduce the susceptibility to possible target antigen escape through the engagement of tumor antigen independent TRAILv.
-